Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

Total article views   Abstract views HTML views PDF downloads Totals
6,619 Dovepress* 5,137 854+ 858 5,991
PubMed Central* 0 628 243 628
Totals 5,137 1,482 1,101 6,619
*Since 29 June 2017
+Since July 2016

View citations on PubMed Central and Google Scholar